Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring
Shinya Abe1,2, Gaku Inoue1,2, Satoru Yamada1,3, Junichiro Irie1,3, Hiroyuki Nojima2, Kaoru Tsuyusaki2, Kensuke Usui2, Koichiro Atsuda2, Toshikazu Yamanouchi41Diabetes Center, Kitasato Institute Hospital, 2Center for Clinical Pharmacy and Clinical Sciences, Kitasato University, 3Department of Interna...
Enregistré dans:
Auteurs principaux: | Abe S, Inoue G, Yamada S, Irie J, Nojima H, Tsuyusaki K, Usui K, Atsuda K, Yamanouchi T |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2011
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/78ab0254b54545f09cc7a8c044ad71cb |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Modern approach to basal-bolus therapy with glargine and glulisine insulin analoguesin various age groups
par: Natalya Nikitichna Volevodz, et autres
Publié: (2013) -
Detemir as a once-daily basal insulin in type 2 diabetes
par: Nelson SE
Publié: (2011) -
On the safety of insulin Glargine
par: Ivan Ivanovich Dedov, et autres
Publié: (2009) -
Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus
par: Lau IT, et autres
Publié: (2017) -
Lantus (Insulin Glargin): new insulin on Russian market
par: Editorial team Diabetes Mellitus
Publié: (2003)